Home Cart Sign in  
Chemical Structure| 877877-35-5 Chemical Structure| 877877-35-5

Structure of TW-37
CAS No.: 877877-35-5

Chemical Structure| 877877-35-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TW-37 is a nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TW-37

CAS No. :877877-35-5
Formula : C33H35NO6S
M.W : 573.70
SMILES Code : O=C(NC1=CC=C(S(=O)(C2=CC=CC=C2C(C)(C)C)=O)C=C1)C3=CC(CC4=CC=CC=C4C(C)C)=C(O)C(O)=C3O
MDL No. :MFCD17010275
InChI Key :PQAPVTKIEGUPRN-UHFFFAOYSA-N
Pubchem ID :11455910

Safety of TW-37

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Bcl-xL

    Bcl-xL, Ki:1.11 μM

  • Mcl-1

    Mcl-1, Ki:0.26 μM

  • Bcl-2

    Bcl-2, Ki:0.29 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
WSU-pre-B-ALL 180 nM 72 hours TW-37 induced apoptosis and inhibited cell proliferation PMC2651908
WSU-DLCL2 300 nM 72 hours TW-37 induced apoptosis and inhibited cell proliferation PMC2651908
WSU-FSCCL 165 nM 72 hours TW-37 induced apoptosis and inhibited cell proliferation PMC2651908
WSU-WM 320 nM 72 hours TW-37 induced apoptosis and inhibited cell proliferation PMC2651908
BxPC-3 250, 500, 750 nmol/L 1 to 3 days TW-37 significantly inhibited cell growth and induced apoptosis in BxPC-3 cells. PMC3798007
Colo-357 250, 500, 750 nmol/L 1 to 3 days TW-37 significantly inhibited cell growth and induced apoptosis in Colo-357 cells. PMC3798007
Human primary renal tubular epithelial cells 800 μM 48 hours To study the effect of TW-37 on PA-induced cell death, results showed that TW-37 reduced PA-BSA-induced cell death. PMC8132466
LLC-PK1 cells 400 μM 48 hours To study the effect of TW-37 on PA-induced cell death, results showed that TW-37 reduced PA-BSA-induced cell death. PMC8132466
Human dermal microvascular endothelial cells (HDMEC) 0.023-50 μM 72 hours Low dose TW-37 displayed a radiosensitizing effect on radiation-treated endothelial cells PMC2946486
Human dermal microvascular endothelial cells (HDMEC) 0.5 μM 3 days Combination treatment with radiation and TW-37 significantly inhibited endothelial cell sprouting PMC2946486
Colo-357 250 nmol/L 72 hours Induction of PAR-4 expression, inhibition of cell growth, and induction of apoptosis PMC3766350
L3.6pl 250 nmol/L 72 hours Induction of PAR-4 expression, inhibition of cell growth, and induction of apoptosis PMC3766350
Primary human dermal microvascular endothelial cells (HDMEC) 1.1 µM 72 hours To evaluate the cytotoxicity and cell cycle effects of TW-37 on HDMEC, results showed that the IC50 of TW-37 was 1.1 µM, and it caused S-phase cell cycle arrest. PMC2709836
Oral squamous cell carcinoma-3 (OSCC-3) 0.3 µM 72 hours To evaluate the cytotoxicity and cell cycle effects of TW-37 on OSCC-3, results showed that the IC50 of TW-37 was 0.3 µM, and it caused S-phase cell cycle arrest. PMC2709836
UM-SCC-1 0.3 µM 72 hours To evaluate the cytotoxicity and cell cycle effects of TW-37 on UM-SCC-1, results showed that the IC50 of TW-37 was 0.3 µM, and it caused S-phase cell cycle arrest. PMC2709836
UM-SCC-74A 0.3 µM 72 hours To evaluate the cytotoxicity and cell cycle effects of TW-37 on UM-SCC-74A, results showed that the IC50 of TW-37 was 0.3 µM, and it caused S-phase cell cycle arrest. PMC2709836
Human primary renal tubular epithelial cells 1% BSA (approximately 150 μM) 2 hours KIM-1-mediated PA-BSA uptake was reduced PMC8132466
LLC-PK1 cells 1% BSA (approximately 150 μM) 24 hours PA-BSA induced cell death and lipid droplet accumulation PMC8132466

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
SCID mice WSU-DLCL2 xenograft model tail vein injection 0.5 mmol/kg Once daily for 3 weeks TW-37 significantly inhibited tumor growth, delayed tumor growth time, and caused tumor cell kill PMC2651908
Mice AA-PA-BSA mouse model Intraperitoneal injection 1000 mg daily daily, at least three weeks To study the effect of TW-37 on PA-induced renal injury, results showed that TW-37 reduced PA-BSA-induced macrophage infiltration and myofibroblast activation. PMC8132466
SCID mice Co-transplantation model of human squamous cell carcinoma (OSCC3) and HDMEC Intraperitoneal injection 15 mg/kg Once daily for 6 days Combination treatment of TW-37 and low dose radiation significantly inhibited tumor growth and increased time to failure PMC2946486
Severe combined immunodeficient mice Colo-357 xenograft model Intravenous injection 50 mg/kg Every 2 days for 10 days TW-37 significantly inhibited tumor growth and induced PAR-4 expression PMC3766350
SCID mice Human tumor angiogenesis model Intraperitoneal injection 15-21 mg/kg Once daily for 7-10 days To evaluate the effect of TW-37 on tumor angiogenesis and tumor progression, results showed that TW-37 significantly inhibited tumor angiogenesis and induced tumor apoptosis without significant systemic toxicities. PMC2709836
Mice KKAy diabetic model Intraperitoneal injection 8 mg/kg Once daily until leukemia symptoms appeared KIM-1-mediated PA-albumin uptake induces renal tubular inflammation and fibrosis PMC8132466

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.74mL

0.35mL

0.17mL

8.72mL

1.74mL

0.87mL

17.43mL

3.49mL

1.74mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories